TG Therapeutics Schedules Key Data Presentations for BRIUMVI

TG Therapeutics to Highlight BRIUMVI at Multiple Sclerosis Forum

NEW YORK — TG Therapeutics, Inc. (NASDAQ: TGTX) is excited to announce a comprehensive schedule of presentations showcasing key data from its pivotal trials involving BRIUMVI (ublituximab-xiiy) for patients managing relapsing forms of multiple sclerosis (RMS). This presentation will take place during the upcoming Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, scheduled for February 27 – March 1, 2025.

Key Presentations Scheduled

These presentations will cover vital insights derived from the ULTIMATE I & II Phase 3 studies and the ENHANCE Phase 3b trial. With a growing patient population facing the challenges of RMS, these findings are critical for informing treatment decisions and improving patient outcomes.

Highlighted Poster Presentations

One of the key presentations is titled "Safety and Tolerability of 30-minute Ublituximab Infusions: Updates from the ENHANCE Study." It will occur on Thursday, February 27, 2025, from 6:45 PM to 7:30 PM ET, showcasing the latest data on infusion protocols and their effects on patient comfort and efficacy.

Another significant presentation is expected to generate interest: "The Design of a Study to Evaluate Fc Biology and Genetic Diversity in Multiple Sclerosis." This session will take place on the same day from 6:00 PM to 6:45 PM ET, led by Nancy Monson, Ph.D., from the University of Texas Southwestern Medical Center.

Overview of Additional Presentations

Additional insights into BRIUMVI’s efficacy will be highlighted in the presentation titled "Real-World Ublituximab Experience at a Single US MS Center". Presented by Dr. John Foley, another critical session on February 28, 2025, aims to discuss real-world usage and patient responses to BRIUMVI in clinical settings.

About the ULTIMATE I & II Phase 3 Trials

ULTIMATE I & II are pivotal double-blind, randomized trials examining BRIUMVI’s effectiveness compared to teriflunomide. These trials enrolled over 1,000 RMS patients across multiple countries and evaluated the therapy over a 96-week period. Patients were carefully selected based on their disease activity, which significantly contributes to the robustness of the results.

BRIUMVI: A Cutting-Edge Treatment

BRIUMVI is an innovative monoclonal antibody designed specifically to target CD20-expressing B-cells, an essential component in the management of autoimmune diseases like RMS. Its unique formulation enables effective B-cell depletion, allowing for better management of the disease with potentially fewer side effects.

Importance for Patients with Multiple Sclerosis

For adults experiencing RMS, BRIUMVI offers a new option as it caters to various forms of the disease, including clinically isolated syndrome and active secondary progressive disease. With nearly 1 million individuals diagnosed with MS in the U.S. alone, advancements like BRIUMVI are crucial in providing effective treatment protocols.

Further Information and Resources

Following the forum, detailed resources regarding the presentations will be made available on TG Therapeutics’ official website, particularly within the Publications section. This will include easy access to all relevant data discussed during the forum.

Frequently Asked Questions

What studies will be presented at the ACTRIMS Forum?

Key studies include data from the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial focusing on BRIUMVI.

Who is the lead author for the presentations?

The lead author for one of the prominent studies is Dr. John Foley, affiliated with Rocky Mountain Multiple Sclerosis.

What is BRIUMVI approved for?

BRIUMVI is approved for treating adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome.

When will the presentations occur?

The presentations are scheduled from February 27 to March 1, 2025, during the ACTRIMS annual forum.

Where can I find more information?

For further information, visit the TG Therapeutics website or refer to the ACTRIMS meeting resources.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.